Acute heart failure: diagnosis and management (CG187)Product type:GuidanceProgramme:Clinical guidelineLast updated: 17 November 2021Published: 8 October 2014
An aortic cuff counterpulsation system for the treatment of heart failureStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Artificial Intelligence assisted echocardiography to support diagnosis of heart failure: Early Value AssessmentStatus:In developmentProgramme:Health technology evaluationExpected publication date: 20 May 2026
CentriMag for heart failure (MIB92)Product type:AdviceProgramme:Medtech innovation briefingPublished: 18 January 2017
Chronic heart failure in adults (QS9)Product type:Quality standardLast updated: 3 September 2025Published: 29 June 2011
Chronic heart failure in adults: diagnosis and management (NG106)Product type:GuidanceProgramme:NICE guidelineLast updated: 3 September 2025Published: 12 September 2018
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 June 2023
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2021
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 November 2023
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac deathStatus:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 4 June 2026
Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (HTG730)Product type:GuidanceProgramme:HealthTech guidancePublished: 24 October 2024
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2014
Implantable Vagus Nerve Stimulator in Heart FailureStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Ivabradine for treating chronic heart failure (TA267)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2012
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Percutaneous insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shockStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: 25 March 2026
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)Product type:GuidanceProgramme:HealthTech guidancePublished: 5 February 2026
Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)Product type:AdviceProgramme:Medtech innovation briefingPublished: 27 July 2018
Rivaroxaban for treating chronic heart failure [ID1462]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years [TSID10350]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 April 2016
Semaglutide for treating obesity-related heart failure with preserved ejection fraction [TSID11788]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shockStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: 25 March 2026
The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)Product type:AdviceProgramme:Medtech innovation briefingPublished: 12 February 2015
The OPTIMIZER smart system for managing heart failure (MIB186)Product type:AdviceProgramme:Medtech innovation briefingPublished: 27 June 2019
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [TSID12347]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) (TA790)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 May 2022
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) (TA731)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 September 2021